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Abstract A at the low concentration of 10 8 mol/1 
. t . , . j . inhibit protein synthesis in lymphocytes 
The sesquiterpene betainyl-anguidine r J • J I r J J -
* Dedicated to Professor A D O L F B U T E N A N D T i s blocked at similarly low concentra-
and the structurally related verrucarin from mouse spieen rapidly after addi-
tion to the cell culture. D N A synthesis 
on the occasion of his 75th birthday. tions whereas R N A synthesis is much 
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less reduced. The following observa-
tions support the notion that D N A syn-
thesis is blocked via inhibition of pro-
tein synthesis: (i) D N A synthesis in a 
cell-free System is not reduced by the 
drug; (ii) in cell culture protein synthe-
sis is inhibited more rapidly and at 
lower concentrations than D N A syn-
thesis; (iii) inhibitors of protein synthe-
sis such as cycloheximide or puromycin 
are similar to betainyl-anguidine in 
their action on lymphocytes whereas 
specific inhibitors of D N A synthesis 
such as cytosine arabinoside or hydroxy-
urea only partially reduce protein syn-
thesis in lymphocytes. 
The sesquiterpene ovalicin at a con-
centration of 10 1 0 mol/1 acts as a very 
potent inhibitor of D N A synthesis in 
proliferating lymphocytes and in lym-
phoma cells. R N A and protein synthe-
sis are only weakly affected. The fol-
lowing observations support the con-
clusion that D N A synthesis is blocked 
only indirectly: (i) D N A synthesis in a 
cell-free System is not reduced by ova-
licin; (ii) a cell-free System for D N A 
synthesis prepared from ovalicin-trea-
ted lymphocytes shows an impaired 
synthetic activity; (iii) in cell culture 
the action of ovalicin is not immediate 
and requires a 8-15 hour period of in-
cubation. 
Introduction 
Fungi produce a large number of 
chemical Compounds which are highly 
toxic either for bacteria or for animals 
and plants. They are toxic because they 
inhibit biochemical reactions essential 
for sustaining life. Their unusual speci-
ficity for either animals and plants or 
bacteria is based on fundamental dif-
ferences existing between molecular 
constituents of the prokaryotic and 
eukaryotic cell. If the receptor for the 
target of such a toxic Compound occurs 
only in a eukaryotic cell exclusively 
this type of cell will be affected. The 
specificity of action is particularly pro-
nounced if such a Compound possesses 
a very high affinity for its target. Then 
very small concentrations are sufficient 
for the inhibitory action to be observed. 
If higher concentrations (10-6 - 10 3 
mol/1) are required the high specificity 
of action may be lost because weak for-
ces such as hydrophobic interactions 
may provoke unspecific binding of 
these Compounds also to other cellular 
constituents with concomitant impair-
ment of their biological functions. 
Therefore Compounds which elicit bio-
logical effects at very low concentration 
command higher interest. 
In recent years the effort to suppress 
the uncontrolled growth of tumor cells 
and other rapidly proliferating cells 
such as committed lymphocytes has 
stimulated a general interest in Com-
pounds which act cytostatic for euka-
ryotic cells. 
In this report the mode of action of 
two diff erent Compounds will be discus-
sed which exhibit a high cytostatic 
activity at very low concentration and 
act exclusively against eukaryotic cells. 
Chemically both Compounds are 
distantly related since they possess the 
basic structure of a sesquiterpene. 
/. A n g u i d i n e a n d r e l a t e d C o m p o u n d s 
Anguidine is produced by various 
species of F u s a r i a and shows mycotoxic 
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anguidine: 
trichothec-9-ene-3,4,15-triol,12,13-epoxy, 
4,15-diacetate, (3a, Aß): 
O 
R t = O H ; R 2 = R 3 = O - C - C H 3 
betainyl-anguidine (chloride): 
O O 
II + II 
Rj = 0 - C - C H 2 - N ( C H 3 ) 3 ; R 2 = R 3 = 0 - C - C H 3 
ci-
verrucarin A : 
R, = H ; R 2 , R 3 = dicarbonic acid ester of: 
O OII C H 3 O 
II I I II 
- 0 - C - C H - C H - C H 2 - C H 2 - 0 - C - C H = C H - C H 
O 
II 
- C H - C - O -
activity. Chemically it is closely related 
with the group of verrucarins [1]. Cy-
tostatic activity of anguidine is obser-
ved at a concentration of 0.5 X 10-8 
mol/1 in mouse mastocytoma cells as 
well as in human tumor cells (KB cells). 
At a similarly low concentration the 
propagation of the D N A containing vac-
cinia virus and its cyptopathogenic eff ect 
is suppressed [2], With respect to the 
molecular target of anguidine it has 
been observed previously that protein 
synthesis in a cell culture is inhibited at 
a concentration of 3 X 10"7 mol/1 in 
eukaryotic cells such as rabbit reticu-
locytes or mouse mastocytoma cells. At 
the same concentration, however, D N A 
synthesis is equally blocked [2]. Synthe-
sis of proteins and of D N A is achieved 
by biochemically very different proces-
ses. Therefore the question arises if an-
guidine acts on such unlike biosynthetic 
pathways by two different independent 
modes of action. This ist not a far-fet-
ched question. For example, it has been 
observed that the antibiotic rifampicin 
specifically blocks R N A synthesis in 
bacteria [3]. On the other hand it inhi-
bits the multiplication of vaccinia virus 
in cell cultures by a completely different 
mechanism [4]. The simultaneous Inhi-
bition of two different biochemical 
reactions, however, may also be explai-
ned without the assumption of two dif-
ferent modes of action if both reactions 
are tightly coupled i n v i v o . 
In view of the observed possibly im-
munosuppressive activity [2] we have 
studied the molecular mode of action of 
anguidine in spieen lymphocytes from 
mice. In the absence of an antigenic or 
mitogenic Stimulus lymphocytes are 
metabolically very inactive. Lympho-
cytes may be induced to proliferate by 
mitogens such as concanavalin A as is 
indicated by a strongly increased syn-
thesis of R N A and proteins followed 
by a rapid synthesis of D N A after 25 h 
of incubation. In most of our experi-
ments we have used the chemically 
modified derivative betainyl-anguidine 
which exhibits the same biological ef-
fects as anguidine but is much better 
soluble in water. If betainyl-anguidine 
is added simultaneously with mitogen 
and radioactively labelled leucine to 
lymphocytes in cell culture the incor-
poration of the radioactively labelled 
amino acid into proteins, determined 
after a 20 h incubation period, is redu-
ced by more than the half in the pre-
sence of only 1 X 1 0 8 mol/1 inhibitor. 
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T a b l e I 
I n h i b i t i o n of p r o t e i n s y n t h e s i s i n l y m p h o c y t e s by b e t a i n y l - a n g u i d i n e o r v e r r u c a r i n A . 
2 fA.% concanavalin A , 10 nmol mercaptoethanol, 5 [AC\ (3H)leucine (resulting specific radioactivity 
in the medium 13 Ci/mol) and inhibitor (as indicated) were added to 106 B6D2 mouse lympho-
cytes from spieen (preincubated at 37° C for 10-20 h) in Eagle's M E M containing 5% fetal calf 
serum (38) (total volume 1.0 ml). After incubation for 20 h at 37° C incorporation of radioactive 
iabel into acid insoluble material was determined (39) (control in the absence of betainyl-angui-
dine: 4731 ± 1 4 9 counts X min" 1; control in the absence of verrucarin A : 8531 ± 9 1 4 counts X 
min"1). 
inhibitor concentration Inhibition of protein 
(M) synthesis in cell culture (%>) 
betainylanguidine 4 X 10*' 20 
1 X 10"8 79 
verrucarin A 4 X 10"9 30 
1 X 10"8 83 
T a b l e I I 
I n f l u e n c e of t h e c e l l c y c l e o n t h e i n h i b i t o r y a c t i o n of v e r r u c a r i n A . 
The experiments were performed essentially as described in table I except that 2 X 10"8 mol/l 
verrucarin A and (3H)leucine were added to the cultures at the time indicated after addition of 
concanavalin A . 
verrucarin A pulse of incorporation incorporation 
added at [3H]leucine in absence of drug 
(h) (h) (cpm) (cpm) 
7. 8 - 1 0 69 412 
15. 16 - 18 81 1079 
39. 40 - 42 45 447 
The same effect is observed x with ver-
rucarin A, a Compound closely related 
to anguidine (table I). Cellular pro-
tein synthesis is blocked rather rapid-
ly. Incubation for only 3 h with 2X10"8 
mol/1 verrucarin Ais sufficient for a very 
strong inhibitory effect to be observed. 
This is observed no matter whether toxin 
is added 7,15 on 39 hours after the mito-
gen (table II). To determine whether the 
synthesis of all cellular proteins is redu-
ced to the same extent the following ex-
periment was performed: 2X10"8 mol/1 
inhibitor was added to stimulated lym-
phocytes which was followed by radio-
actively labelled methionine one hour 
later. After two more hours the cellu-
lar proteins were separated by Polya-
crylamide gel electrophoresis in pre-
sence of dodecylsulfate. Except for a 
single protein zone migrating with the 
relative electrophoretic mobility of 0.52 
the synthesis of all other radioactively 
labelled proteins is uniformly reduced 
(Fig 1). This is also true for the biosyn-
thesis of histones as will be discussed 
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8 6 4 
m i g r a t i o n [cm] 
< 
2 
e 
F i g . 1 . G e l - e l e c t r o p h o r e t i c a n a l y s i s of r a d i o a c t i v e p r o t e i n s s y n t h e s i z e d d u r i n g i n c u b a t i o n of s t i m u -
l a t e d l y m p h o c y t e s w i t h (^S) m e t h i o n i n e i n t h e presence o r absence of b e t a i n y l - a n g u i d i n e . 
5X10 7 lymphocytes stimulated as described in table III, were incubated for 39 h at 37° C . 1 h after 
addition of 2X10" 8 M betainyl-anguidine (BAC) 0.25 mCi (^S) methionine (specific radioactivity 
20 Ci/mol) were added and the incubation continued for 2 h. Subsequently the cells from 4.5 ml 
of the incubation mixture were isolated by centrifugation. After washing witfc cold 0.85% N a C l 
half of the cells were lysed for 10 min at room temperature by suspending them in about two 
volumes 60 m M tris-HCl p H 6.8 containing 10% glycerol and 2.7% dodecylsulfate (total volume 
50 fi\). 20 /u\ of this mixture (equivalent to 10e cells) were applied to a slab gel containing a linear 
gradient of 5-15% acrylamide with 0.1 % dodecylsulfate. Electrophoresis was carried out at 60 V 
overnight [43]. Autoradiography was performed with the dried slab gel for 6 days. The developed 
film was scanned with a densitometer. 
below. Histones are proteins tightly 
associated with D N A in eukaryotic 
cells. 
These observations support the con-
clusion that in lymphocytes anguidine 
and related Compounds act in general 
at very low concentration on protein 
synthesis. Furthermore, the action of 
anguidine and its derivatives is not 
restricted to a certain type of cell such 
as lymphocytes or to a certain species 
of animal as follows from experiments 
with rabbit reticulocytes [5] and HeLa 
cells [6]. Since they are effective at 
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lower concentrations than other inhibi-
tors of protein synthesis such as puro-
mycin or cycloheximide (table VI and 
VIII and unpublished experiments) 
their general application in biochemical 
and biological experiments is suggested. 
On the other hand, derivatives of 
anguidine also act as very potent inhi-
bitors of D N A synthesis as is shown by 
the following experiment: inhibitor is 
added together with mitogen to a cell 
culture of stimulated lymphocytes. 
When D N A synthesis is determined by 
incubation with radioactively labelled 
thymidine a 50% inhibition is observed 
in the presence of only 0.7 X 10 8 mol/1 
of the drug, similar to the inhibition of 
protein synthesis. Doubling of the con-
centration of the inhibitor leads to a 
complete inhibition. Verrucarin A is 
even more active. D N A synthesis is in-
hibited at a 10 fold lower concentra-
tion than protein synthesis (table III). 
Obviously anguidine is a very potent 
T a b l e I I I 
I n h i b i t i o n of D N A s y n t h e s i s i n l y m p h o c y t e s by b e t a i n y l - a n g u i d i n e , v e r r u c a r i n A o r o v a l i c i n 
s t u d i e d i n c e l l c u l t u r e a n d i n a c e l l - f r e e S y s t e m . 
100 concanavalin A, 0.5 ^amol mercaptoethanol and betainyl-anguidine were added to 5X107 
lymphocytes in medium (see table I) (total volume 45 ml). After 38 h incubation at 37° C 0.9 ml 
aliquots of the cell Suspension were transferred to test tubes containing 1 ^uCi (3H)thymidine 
(specific radioactivity 6.7 Ci/mmol). Incorporation of radioactive label into acid insoluble material 
was determined after 8 h incubation at 37° C . Control without betainyl-anguidine: 26817±1351 
counts X min"1. The experiments with verrucarin A in cell culture were performed essentially as 
described in table I except that (3H)leucine was omitted. After 36 h incubation 0.1 ml medium 
containing 1 ^wCi ( 3H) thymidine (specific radioactivity 2 Ci/mmol) and 10 nmol mercaptoethanol 
was added. 18 h later incubation was terminated. Control wihout verrucarin A : 9016±1784 
counts X min"1. Experiments with ovalicin in cell culture: 1 ,wg concanavalin A and inhibitor was 
added to 106 lymphocytes preincubated for 12 h. After 38 h 1 ^ C i (3H)thymidine (specific 
radioactivity 6.7 Ci/mmol) was added and incubation continued for 3 h. Control without ovalicin: 
61843 ±2313 counts X min' 1 . Synthesis of D N A in a cell-free System was measured essentially as 
described [7]. Nuclei were from lymphocytes stimulated for 46 h with concanavalin A in presence 
of 10 ftM mercaptoethanol in the experiment with betainyl-anguidine (as in table I). In the 
experiment with ovalicin mercaptoethanol was left out. Incubation of the cell-free System was 
45 min at 37° C . Control without betainylanguidine: 1890 counts X min"1 X 10'6 nuclei; control 
without ovalicin: 436 counts X min"1 X 10"6 nuclei. 
inhibitor concentration of drug inhibition of D N A synthesis (°/o) 
(M) in cell culture in a cell-free System 
betainyl-anguidine 4 X 10"9 12 
1 X 10"8 98 
2 X 10"6 - 7 
verrucarin A 4 X 10"9 33 
1 X 10"9 96 
ovalicin 2 X 10"10 50 
4 X 10"10 73 
3 X 10"6 75 0 
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inhibitor of the synthesis of proteins as 
well as of D N A in lymphocytes. This f act 
has to be taken into consideration when 
discussing the molecular mode of action 
of this drug. In the case of verrucarin 
A D N A synthesis is even more sensitive 
than protein synthesis. Consequently 
we have to investigate the question if 
anguidine derivatives are double-hea-
ded inhibitors or if they block a pro-
cess common to both protein and D N A 
synthesis. 
Such a process would be the produc-
tion of energy in the form of A T P 
required for both biosynthetic reactions. 
However this is not the case as is shown 
by the following argument. Biosynthe-
sis of R N A also requires energy in the 
form of A T P . However, R N A synthesis 
in lymphocytes is much less reduced by 
a concentration of the inhibitor which 
inhibits protein synthesis distinctly wit-
hin 3 h. Even 100 fold higher concentra-
tions of the drug reduce R N A synthesis 
by only 50% (table IV). Such a relati-
vely weak effect on R N A synthesis has 
been previously observed in mouse 
mastocytoma cells [2]. Of course, there 
are many other biochemical pathways 
which precede both D N A and protein 
synthesis. Any of them could be the 
target of anguidine. Instead of discuss-
ing them separately we would like to 
mention several arguments which sup-
port the notion that anguidine and its 
derivatives block D N A synthesis via 
the inhibition of protein synthesis. 
(i) D N A synthesis in a cell-free 
System ist not inhibited by derivatives 
of anguidine. This process can be stu-
died with nuclei obtained from stimu-
lated lymphocytes [7]. During incuba-
tion of this System the activated precur-
sors of D N A , the four deoxynucleoside 
T a b l e I V 
C o m p a r i s o n of i n h i b i t o r y a c t i o n of b e t a i n y l - a n g u i d i n e o n R N A - a n d p r o t e i n s y n t h e s i s . 
Inhibition of protein synthesis (3 h incubation): similar to experiments described in Fig 1 except 
that after 40 h incubation 0.9 ml aliquots of the cell Suspension was added to 0.1 ml Hank's 
Solution containing inhibitor. After 1 h (8H)leucine was added and incorporation determined 
after another 2 h at 3 7 ° C (control without drug: 1 6 2 2 9 ± 3 0 1 0 counts X min"1); 20 h incubation: 
essentially as described in table I (control without drug 4731 ± 1 4 9 counts X min"1). Inhibition 
of R N A synthesis: 3 h incubation with drug: drug was added to 106 lymphocytes (table 1), 18 h 
after concanavalin A . 2 hours later 50 nCi (1 4C)uridine (specific radioactivity 415 (Ci/mol) was 
added and incorporation into acid insoluble material determined after 1 h (control without drug 
693 ± 2 1 counts X min"1). 12 h incubation with drug: concanavalin A, (1 4C)uridine and drug 
were added together to the lymphocytes. Incorporation was determined after 12 h incubation 
(control without drug: 5 0 9 4 ± 4 0 9 counts X min"1). 
percent inhibition of incorporation of 
betainyl-anguidine (M) leucine after uridine after 
3 h 20 h 3 h 12 h 
incubation with drug incubation with drug 
2 X 10"8 62 95 28 41 
1 X 10"7 96 100 - 50 
2 X 10"6 - 52 69 
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T a b l e V 
Dependence of i n h i b i t o r y a c t i o n of b e t a i n y l - a n g u i d i n e o n p r o t e i n o r D N A s y n t h e s i s o n t h e t i m e 
of i n c u b a t i o n . 
Stimulated lymphocytes as described for the experiments in cell culture with betainyl-anguidine in 
table III were used. Short incubation with drug: 40-43 h after addition of concanavalin A ; long 
incubation with drug: 0-40 h after addition of concanavalin A ; protein synthesis was measured 
by incubation with (3H)leucine for 2 h; D N A synthesis was determined by incubation with 
(3H)thymidine for 2 h. 
incubation period with molar concentration of drug required for 
betainyl-anguidine 50 percent inhibition of 
protein synthesis D N A synthesis 
short 1,5 X 10'8 5,0 X 10"8 
long 0,5 X 10'8 0,5 X IQ'8 
triphosphates dATP, dTTP, dGTP and 
dCTP, are incorporated into D N A Even 
in the presence of 2X10"6 mol/1 betain-
ylanguidine this reaction is only slightly 
reduced (table III). 
(ii) In a cell culture protein synthesis 
is inhibited more rapidly and at lower 
concentration of the drug than D N A 
synthesis. Comparing the inhibitory 
effects of betainyl-anguidine observed 
after a long or a short incubation period 
it is immediately obvious that the inhi-
bition of protein synthesis decreases 
much less than that of D N A synthesis 
upon shortening the incubation time. 
The concentration of the inhibitor has 
to be increased by a factor of ten to in-
hibit D N A synthesis to the same extent 
as protein synthesis during a short expo-
sure to the drug (table V). 
(iii) Specific inhibitors of protein 
synthesis such as puromycin or cyclo-
heximide inhibit D N A synthesis in 
lymphocytes similarly to the derivati-
ves of anguidine. This conclusion is 
derived from the Observation that puro-
mycin or cycloheximide inhibit D N A 
synthesis in stimulated lymphocytes at 
the same concentration as protein syn-
thesis. Similar to betainyl-anguidine the 
effect of cycloheximide on D N A syn-
thesis increases with the length of the 
exposure time. Smaller concentrations 
of the inhibitor are sufficient at a long 
incubation time (table VI). 
All these observations are consistent 
with the hypothesis that protein bio-
synthesis is the primary target of angui-
dine and its derivatives. Subsequently 
D N A synthesis ceases. This effect is due 
to the tight coupling of D N A synthesis 
to protein synthesis in eukaryotic cells 
[8] which has been demonstrated with 
a large number of inhibitors of protein 
synthesis and by use of amino acid ana-
logues in many different types of cells 
[9-15]. Probably the tight coupling is 
mediated by the process of histone bio-
synthesis which is absolutely required 
for the formation of chromatin [16-18]. 
D N A biosynthesis can not be the pri-
mary target of anguidine. Otherwise 
any blocking of D N A synthesis by spe-
cific inhibitors should lead to a general 
termination of protein biosynthesis. This 
question was studied in the f ollowing ex-
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T a b l e V I 
I n f l u e n c e of i n h i b i t o r s of p r o t e i n s y n t h e s i s o n t h e D N A s y n t h e s i s i n l y m p h o c y t e s . 
The effect of puromycin on protein synthesis was measured under conditions similar to those 
described in table I except that puromycin was added 39 h after concanavalin A. 1 h later the 
cells were isolated by centrifugation and resuspended in medium containing, in addition to 
mitogen, mercaptoethanol and puromycin, 5 ,«Ci (3H)leucine (specific radioactivity 50 Ci/mol). 
Incorporation was determined after 1 h. Control without puromycin: 4800 counts X min"1. For 
measuring D N A synthesis the isolated cells were resuspended in medium as above except that 
(3H)leucine was replaced by 1 fxQX (3H)thymidine. Incorporation was determined after 1 h. 
Control without puromycin: 6800 count X min" 1. Experiments with a 6 h incubation of drug: 
similar to those described in table III with betainyl-anguidine except that betainyl-anguidine or 
cycloheximide were added 38 h after concanavalin A . 4 h later 1 p C i (3H)thymidine or 5 / *Ci 
(3H)leucine were added and incorporation determined after 2 h. Controls without drug: incor-
poration of (3H)leucine 15850 counts X min" 1; incorporation of (3H)thymidine 20705 counts 
X min"1. Experiments with cycloheximide or betainyl-anguidine (incubation with drug for 2 or 
12 h resp.): similar to table III except that drug was added either 29 or 39 h after concanavalin A . 
1 /aCi(3H)thymidine was added 40 h after mitogen and the incubation terminated after 1 h. 
Control without cycloheximide (2 h pulse): 4642 counts X min" 1; (12 h pulse): 11242 counts X 
min" 1; control without betainyl-anguidine (2 h pulse): 3972 counts X min' 1 ; (12 h pulse): 10886 
counts X min" 1. 
inhibitor concentration period percent inhibition of incorporation 
(M) of incubation of 
with drug (h) leucine thymidine 
puromycin 1,0 X 10"4 2 93 87 
cycloheximide 7,2 X 10"7 6 86 70 
betainyl-anguidine 0,2 X 10"7 6 92 83 
cycloheximide 1,8 X 10"7 2 - 4 
12 - 67 
betainyl-anguidine 0,2 X 10"7 2 - 7 
12 - 85 
rapidly and more efficiently than D N A 
synthesis during a short incubation 
(table V). Therefore D N A synthesis is 
hardly the primary target of this drug. 
If protein synthesis i n v i v o is the pri-
mary target of anguidine one would 
expect that this drug is also a very 
potent inhibitor of protein synthesis in 
a cell-free ribosomal System. Indeed, it 
has been demonstrated previously by 
many investigators that this classs of 
Compounds inhibits initiation as well 
as elongation of protein synthesis on 
eukaryotic ribosomes in a cell-free 
periments: Cytosine arabinoside2 inhi-
bits D N A synthesis in stimulated lym-
phocytes. Simultaneously biosynthesis of 
histones but not of other proteins de-
creases strongly (Fig. 2). Similarly hy-
droxyurea3 inhibits D N A synthesis in 
lymphocytes much more strongly than 
protein synthesis (table VII). Contrary 
to these inhibitors of D N A synthesis 
anguidine blocks protein synthesis more 
2 an antimetabolite of biosynthesis of dCTP. 
3 a potent inhibitor of ribonucleoside di-
phosphate reductase, of an enzyme required for 
the synthesis of D N A precursors. 
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F i g . 2 . G e l - e l e c t r o p h o r e t i c a n a l y s i s of r a d i o a c t i v e l a b e l l e d n u c l e a r p r o t e i n s s y n t h e s i z e d d u r i n g 
i n c u b a t i o n of s t i m u l a t e d l y m p h o c y t e s w i t h ( 1 4 C ) l e u c i n e i n t h e presence o r absence c y t o s i n e 
a r a b i n o s i d e . 
Experiments were performed similar to Fig. 1 except that 20 ^wCi (14C)leucine (specific radio-
activity 309 Ci/mol) and 4.5 X10" 5 M cytosine arabinoside were added. After incubation nuclei 
were prepared as described [7] and dissolved in dodecylsulfate as in Fig. 1. To resolve the 
histones the gel System described [44] was used. Nuclear proteins [7] from 2X10 6 lymphocytes 
were applied to the gel. 
Table V I I 
I n f l u e n c e of i n h i b i t o r s of D N A s y n t h e s i s o n p r o t e i n s y n t h e s i s i n l y m p h o c y t e s . 
Experiments were performed similarly to those described in table III except that the drug in 0.1 ml 
medium was added to 0.9 ml aliquots of stimulated lymphocytes 39 hours after mitogen. One 
hour later (3H)thymidine or (3H)leucine were added and incorporation into acid insoluble 
material measured after another 2 hours of incubation; controls without drug for D N A syn-
thesis: 1) 14381 ± 1 0 4 6 counts X min"1 (experiments with hydroxyurea); 2) 12240 ± 7 5 5 counts X 
min"1 (experiments with cytosine arabinoside). Controls without drug for protein synthesis: 
1) 8 9 1 7 ± 2 2 3 (experiments with hydroxyurea); 2) 6240 counts X min"1 (experiments with cytosine 
arabinoside). 
inhibitor concentration percent inhibition of incorporation of 
(M) thymidine leucine 
hydroxyurea 1,3 X 10"4 77 10 
13,0 X 10"4 96 36 
cytosine 4,1 X 10"7 65 0 
arabinoside 41,0 X 10"7 91 10 
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T a b l e V I I I 
I n f l u e n c e of i n h i b i t o r s of p r o t e i n s y n t h e s i s i n c e l l c u l t u r e o n t h e r i b o s o m a l s y n t h e s i s of p r o t e i n s 
i n a c e l l - f r e e S y s t e m . 
Experiments in cell culture: Essentially as described in table IV except that verrucarin A or 
betainyl-anguidine were added 39.5 h after concanavalin A and (3H)leucine 30 min later. 
Incubation was terminated 1 h later. Experiments with cycloheximide were carried out similarly 
to the experiments in cell culture with betainyl-anguidine described in table III except that the 
drug was added 38 h after concanavalin A. 2 h later (3H)leucine was added and the incubation 
continued for 2 more hours. I n v i t r o experiments: essentially as described [40] with rat liver 
supernatant [41]. Ribosomes were prepared from lymphocytes stimulated for 42 h with concan-
avalin A (table III). Experiments with added m R N A : 50 ,«g poly rU and 1 /uCl (3H)phenylalanin 
(specific radioactivity 9 Ci/mmol); time of incubation 40 min except for cycloheximide (20 min); 
control without drug: about 4100 counts X min"1 in both experiments. In the experiments using 
endogenous m R N A 1 ^ C i (3H)leucine was used as radioactive precursor; time of incubation: 
20 min. Control without drug: 5195 counts X min - 1 . 
inhibitor molar concentration required for 
50 percent inhibition of protein synthesis 
in ce 11 culture in a cell-free System 
poly U endogenous m R N A 
no effect at 
verrucarin A 2 X 10"8 2 X 10'5 2 X 10"5 
betainyl-anguidine 2 X 10*8 2 X 10'5 > 2 X 10"4 
cycloheximide 4 X 10'7 4 X 10*4 1 X 10'3 
system [5, 6, 19-25]. It is rather strik-
ing, however, that usually more than 
10"6 mol/1 anguidine or verrucarin A 
are required for inhibition under these 
conditions. We have confirmed these 
Observation for the inhibition of protein 
synthesis in a cell-free system with ribo-
somes from stimulated lymphocytes 
using either polyribouridylic acid or 
endogeneous R N A as messenger. To 
obtain 50% inhibition 2 X 10"5 mol/1 
of the toxin is required (table VIII). 
Obviously in this system protein syn-
thesis is also much less sensitive to betai-
nyl-anguidine than in cell culture. This 
unexpected discrepancy between the 
effect in cell culture and in a cell-free 
system has been observed with other 
inhibitors of protein synthesis such as 
cycloheximide [20, 26-28] and emetine 
[12, 28] in various eukaryotic cells and 
cellfree Systems. We have confirmed the 
Observation with cycloheximide in sti-
mulated lymphocytes (table VIII). It 
may be explained by assuming the pre-
sence or absence of a soluble protein 
factor which determines the sensitivity 
to the inhibitors. On the basis of this 
assumption the concentration of such a 
soluble factor would control the inhibi-
tory activity of the drugs. Indeed, such 
a soluble protein has been isolated 
from the supernatant of a yeast lysate 
which renders sensitivity towards cy-
cloheximide to the cell-free system from 
yeast [29]. 
//. O v a l i c i n 
Ovalicin has been isolated from the 
culture medium of the ascomycete Pseud-
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Ovalicin 
eurotium ovalis STOLK by SIGG and 
WEBER . The same authors have deter-
mined its chemical structure [30]. Its im-
munosuppressive activity i n v i v o deser-
ves particular attention: the number of 
antibody producing cells in the spieen 
of mice immunized with sheep red 
blood cells decreases to less than one 
per cent if 600 mg ovalicin per kg mou-
se is injected one day after immunisa-
tion. With later injection the inhibitory 
effect declines rapidly. Similarly the 
graft versus host reaction is distinctly 
delayed by ovalicin. The drug reduces 
the number of mitoses in spieen cells 
of immunised mice whereas the mitotic 
index in the jejunum is unchanged [31, 
32]. These observations suggested a 
study of the action of ovalicin on cells 
of the lymphatic system. Following our 
proposal SCHIMPL and WECKER have 
investigated the effect of the drug on the 
induction of antibody production in 
cultures of mouse spieen cells [33]. Sur-
prisingly the activity of ovalicin in this 
system turned out to be much higher 
than in the animal. Even at a concen-
tration of 4 X 1 0 9 mol/1 a distinct in-
hibition was observed [34]. One reason 
for the apparently lower activity in the 
animal may be the much higher meta-
bolic turnover rate of the drug. 
We decided to analyse the mode of 
action of ovalicin by measuring a more 
convenient reaction in a lympocyte cell 
culture system. For this purpose we 
have chosen thymidine incorporation 
into D N A as an indicator of cell proli-
feration in lymphocytes stimulated by 
mitogen. If ovalicin is added together 
with concanavalin A to murine splenic 
lymphocytes incorporation of radio-
actively labelled thymidine into D N A 
during the S-phase is strongly reduced. 
Even at a concentration of 2 X 1 0 1 0 
mol/1 ovalicin a 5 0 % decrease of thy-
midine incorporation is observed (table 
III). However, at much higher concen-
trations of the drug inhibition of D N A 
synthesis is by no means complete. The 
extent of this ovalicin resistant thymi-
dine incorporation depends on many 
factors such as the concentration of the 
mitogen, cell density, presence of mer-
captoethanol or time of measurement 
of D N A synthesis. 
Ovalicin is not only active on D N A 
synthesis induced artificially by plant lec-
tins such as concanavalin A, purified phy-
tohaemagglutinin or poke weed mitogen 
(data not shown). In a mixed lympho-
cyte culture proliferation is induced by 
the presence of several different anti-
genic determinants on the cell surface 
of the allogeneic lymphocytes. In this 
system ovalicin also is strongly inhibi-
tory to D N A synthesis (table IX). 
Al l these observations demonstrate 
that ovalicin is one of the most potent 
low-molecular inhibitors of prolifera-
tion of lymphocytes. 
A Suspension of spieen cells contains 
populations of many different cells, 
among them lymphocytes of B and T 
type. Therefore the question arises if 
ovalicin inhibits proliferation only in 
certain types of cells. B and T cells may 
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T a b l e I X 
I n f l u e n c e of o v a l i c i n o n t h e t h y m i d i n e i n c o r p o r a t i o n i n t o p r o l i f e r a t i n g l y m p h o c y t e s . 
M i x e d l y m p h o c y t e c u l t u r e : A mixture of 5 X10 5 spieen lymphocytes each from C 57 Bl/6 and DBA/2 
mice were incubated at 3 7 ° C with or without drug inEagle's M E M containing 5°/o fetal calfserum 
[38] (total volume 1 ml). After 48 h / * C i (3H)thymidine (specific radioactivity 10 Ci/mmol) 
were added and the incubation continued for 6 h. 
L y m p h o h l a s t o m a c e l l s : Exponentially growing cells were cultured at 37° C in Dulbecco's modified 
Eagle's medium (without nonessential amino acids) containing 10% fetal calf serum (total volume 
15 ml) with or without drug. After 48 h 0.9 ml aliquots were transferred to test tubes, 1 f t C i 
(3H)thymidine (specific radioactivity 0.5 Ci/mmol) in 0.1 ml was added and the incubation 
continued for 1 h. 
Spleen c e l l s ( a t h y m i c n u l n u m o u s e ) : 106 cells were incubated in the presence of 2 (A,% lipopolysac-
charide and ovalicin for 36 h (total volume 1 ml). Subsequently 1 ^ C i (3H)thymidine was added 
and the incubation continued for 24 h. 
H u m a n p e r i p h e r a l b l o o d l y m p h o c y t e s : lymphocytes from fresh human blood (42) were treated as 
described under spieen cells except that 5 ^ug/ml Concanavalin A was used as mitogen. 
type of cell ovalicin (mol/1) incorporation of [3H] thymidine 
(counts X min'1) inhibition 
+ ovalicin — ovalicin (°/o) 
mixed mouse lymphocytes 0,3 X 10' 1 1 2538 ± 917 6471 ± 1305 61 
(C 57 Bl/6 + D B A 2) 
S 49.1 lymphoblastoma 1,0 X 10'9 35410 ± 760 70820 ± 340 50 
spieen cells 
(athymic nu/nu mouse) 3,0 X 10-7 4609 ± 343 13557 ± 1213 65 
peripheral human lymphocytes 2,0 X 10-7 1971 ± 260 3131 ± 226 37 
be stimulated separately by various 
mitogens such as concanavalin A which 
induces only T cells whereas lipopoly-
sacdiaride from the outer membrane of 
gram-negative bacteria induces only B 
cells [35], In each case the proliferation 
induced by these type-specific mitogens 
is inhibited by very small concentra-
tions of ovalicin (table IX). This is also 
true for the mitogen induced prolifera-
tion of human peripheral lymphocytes 
(table IX). Similarly, thymidine incor-
poration in transformed lymphocytes 
such as monoclonal S 49.1 mouse lym-
phoma cells [36] is strongly reduced 
after 48 h incubation with the toxin 
(table IX). This Observation demonstra-
tes the direct action of ovalicin on 
lymphocytes. Its action is not mediated 
by cell-cell interaction, for example via 
macrophages. 
The inhibitory action of ovalicin on 
cells different from those of the lym-
phatic system has also been studied. 
Thymidine incorporation in 3T6 mouse 
fibroblasts or HeLa cells is distinctly 
less inhibited by ovalicin. Incubation 
with 2 X l O 7 mol/1 drug for two days 
results in only 30-40 % inhibition 
whereas at this concentration inhibition 
in S 49.1 lymphoma cells is 80% at this 
concentration. However, the smaller in-
hibitory effect on 3T6 or HeLa cells is 
already detectable at the low drug con-
centration of 2 X l O 9 mol/1 (data not 
shown). These observations suggest 
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that lymphocytes are more susceptible to 
the action of ovalicin than other cells, 
in agreement with observations on the 
eff ects of the drug on the various animal 
tissues [31]. 
In the experiments reported so far 
incorporation of the nucleoside thymi-
dine into D N A was used as analytical 
tool to demonstrate the activity of ova-
licin. If D N A synthesis is directly affec-
ted the drug should be able to block the 
incorporation of deoxyribonucleoside 
triphosphates into D N A in a cell free 
system from lymphocytes [7]. Howe-
ver, even at concentration of 3 X 10*6 
mol/1 ovalicin does not act inhibitory 
in this system (table III). Obviously 
the polycondensation of precursors to 
D N A is not the target of the drug. On 
the other hand D N A synthesis is clearly 
reduced in a cell-free system prepared 
from lymphocytes which had been 
preincubated with ovalicin compared 
with the activity of a system from 
untreated cells (table X). This Observa-
tion supports the notion that ovalicin 
inhibits the formation of an essential 
element of the D N A synthesizing 
machinery. 
If this notion is correct it is be expec-
ted that the time of addition of the in-
hibitor to the cell culture should clearly 
influence the extent of inhibition. In-
deed, this notion has been confirmed. 
If ovalicin is added to a spieen cell cul-
ture at various times after mitogenic 
Stimulation maximal inhibition is ob-
served only when the drug is added 
until the 6th to the 8th hour after mito-
gen. If added 16-20 h after mitogen no 
effect is measured on the D N A synthesis 
measured 14 h later (Fig. 3). Obvious-
ly the early phase of lymphocyte Stimu-
lation is particularly sensitive to the 
inhibitor. 
On the other hand, characteristic 
reactions occurring immediately after 
addition of the mitogen are not at all 
reduced by the drug. This conclusion 
may be derived from the Observation 
that ovalicin added 6 h after the mito-
gen shows its füll inhibitory activity 
(Fig. 3). The same conclusion is derived 
from the investigation of the lipid 
T a b l e X 
I n f l u e n c e of o v a l i c i n o n t h e i n c o r p o r a t i o n of ( * H ) d T T P i n t o D N A of n u c l e i of l y m p h o c y t e s . 
The experiment was performed as described in table III except that nuclei were prepared from 
lymphocytes (2X10 6 cells/ml) stimulated for 46 h with 1 ,ug/ml concanavalin A in the absence of 
mercaptoethanol; concentration of ovalicin: 7X10" 7 mol/1. 
pretreatment of [3H] d T T P incorporation into nuclei 
lymphocytes (counts X min"1 X 10*6 nuclei) 
+ Con A 115 
4- ovalicin 
+ Con A 231 
— ovalicin 
— Con A 31 
— ovalicin 
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addition of ovalicin after mitogen (h) 
F i g . 3. I n f l u e n c e o f t h e t i m e of a d d i t i o n of o v a l i c i n o n ( s H ) t h y m i d i n e i n c o r p o r a t i o n i n t o D N A of 
s t i m u l a t e d l y m p h o c y t e s . 
1 /ig/ml concanavalin A was added to 106 lymphocytes (preincubated for 12 h at 37° C). 2X10* 7 M 
ovalicin were added after the time indicated on the abscissa. 30 h after mitogen (3H)thymidine 
was added and the incubation continued for 6 h. Controls without ovalicin: 2 1 8 3 5 ± 1 0 9 4 countsX 
m i n 1 = 100%. 
turnover which, in lymphocyte mem-
branes, is significantly increased very 
soon after addition of mitogen [37]. 
The lipid turnover is increased also in 
presence of ovalicin (table XI). 
These observations may lead to the 
conclusion that ovalicin acts on stimu-
lated lymphocytes only during a very 
short phase of the cell cycle (6-12 h 
after addition of mitogen). However, 
this conclusion could not be confirmed. 
Rather a 14-16 h incubation period of 
the drug is required for maximum in-
hibition of stimulated spieen lympho-
cytes from mouse as is shown by the 
following experiments: in the first ex-
periment the drug was added to the cell 
culture various times after the mitogen. 
20 h after addition of the mitogen the 
inhibitor was removed from all samp-
les by repeated washing (Fig. 4 (•)). 
The strongest inhibition of D N A syn-
thesis was observed when ovalicin had 
acted on the cells for at least 16 h. In 
the second experiment the drug was 
added uniformly to all samples 6 h 
after mitogen. It was then removed 
from the samples after 2-14 h incuba-
tion (Fig. 4 ( ± ) ) . As in the previous 
experiment an incubation period of at 
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T a b l e X I 
I n f l u e n c e of o v a l i c i n o n t h e i n c o r p o r a t i o n of ( u C ) a c e t a t e i n t o l e c i t h i n f r o m l y m p h o c y t e s . 
Lymphocytes from spieen (2X10 6 cells/ml, preincubated for 15 h) were incubated in Eagle's M E M 
containing 2.5% calf serum, 1 a^g/ml concanavalin A and 10 u^mol/1 mercaptoethanol. Incorpora-
tion of ( 1 4C) acetate (56 Ci/mol) into lecithin was measured essentially as described [37]. Concen-
tration of ovalicin: 2X10" 7 mol/l (added with Con A). 
additions incorporation of [14C]acetate into 
lecithin from lymphocytes 
between 0-4 h after addition 
of Con A (counts X min"1) 
lecithin content 
(in % of total lipids) 
+ Ccn A 904 15.6 
+ ovalicin 
+ Con A 803 14.3 
— ovalicin 
— Con A 567 13.5 
— ovalicin 
least 14 h is required to obtain the 
strongest inhibitory effect. This long 
incubation period may be required for 
several reasons: existence of various 
populations of cells in the culture, a 
very slow permeation of the drug into 
the cells or a metabolic activation of 
ovalicin. 
However we were unable to detect 
any metabolic products in the medium 
of the cell culture after a long incuba-
tion with the drug which would inhibit 
stimulated lymphocytes with higher 
activity (data not shown). 
The preceding experiments show that 
the cell cultures have to be incubated 
with ovalicin for a rather long period 
of time to obtain a maximal inhibitory 
effect. But at which time can the first 
effect of the drug be observed? If the 
rate of D N A synthesis is measured 
using short pulses of radioactively 
labelled thymidine and starting imme-
diately after addition of mitogen, an 
incorporation of thymidine into D N A 
is observed as soon as 7-8 h after mito-
gen (Fig. 5). Although exceedingly 
small, it is clearly higher than that ob-
served in a cell culture not having 
received mitogen. If 2 X 10"7 mol/1 
ovalicin are added together with the 
mitogen even this very early incorpora-
tion is distinctly inhibited (Fig. 5). 
Again the effect of ovalicin is not obser-
ved immediately after addition but 
requires an incubation period of several 
hours (data not shown). 
Al l these observations are at variance 
with D N A synthesis as a direct target 
of the drug. Therefore the action of the 
toxin on the biosynthesis of other mac-
romolecules has also been investigated. 
Incorporation of radioactively la-
belled uridine into the acid insoluble 
material of cell lysate was used to assay 
for the biosynthesis of R N A . Incorpo-
ration of uridine into R N A is signifi-
cant even in resting lymphocytes. It is 
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time (h) of addition of drug {•) 
16 12 8 i* 0 
0 U 8 12 16 
time(h) of removal of drug W —* 
F i g . 4 . I n f l u e n c e of t h e l e n g t h of i n c u b a t i o n p e r i o d of l y m p h o c y t e s w i t h o v a l i c i n o n t h e i n h i b i t i o n 
of D N A s y n t h e s i s . 
1 4«g ConA was added to 106 lymphocytes (preincubated for 12 h at 37° C) in 1 ml medium. In 
one series of experiments (•) 3X10" 9 M ovalicin were added after addition of ConA at the time 
indicated on the upper abscissa and the drug removed 20 h after addition of mitogen by sedimen-
ting of the cells and resuspending in fresh medium. This washing procedure was repeated twice. 
Controls were treated similarly. 25 h after addition of mitogen 1 ^uCi (3H)thymidine was added 
and the incubation continued for 11 h. In a second series of experiments (A) 3X10" 8 M ovalicin 
were added 6 h after mitogen and removed by repeated washings after the times indicated on the 
lower abscissa. Controls without drug: 29198 ± 2 6 8 9 counts X min' 1 = 100%. 
not reduced even by 3 X 10"7 mol/1 
ovalicin. In lymphocytes stimulated 
with concanavalin A R N A synthesis is 
only weakly inhibited after 20 h incu-
bation with the drug (Table XII). Ob-
viously, R N A synthesis as followed by 
total incorporation of a precursor, is 
not the target of the drug. 
Furthermore, this Observation also 
indicates that the production of energy 
in lymphocytes is not the target of ova-
licin because R N A synthesis is strongly 
dependent on this process. 
In eukaryotic cells, D N A synthesis 
is tightly coupled to protein synthesis 
as has been discussed in the section on 
anguidine. Therefore the influence of 
ovalicin on protein synthesis has been 
investigated. The 'incorporation of 
radioactively labelled leucine into the 
acid insoluble material of cell lysates 
was used to assay for protein biosyn-
thesis. 14 h incubation with 2 X 10'7 
mol/1 ovalicin leads to a 20 % reduction 
of protein synthesis whereas the small 
extent of D N A synthesis is already redu-
248 Hartmann et al. 
10 12 14 16 
incubation (h) after addition of mitogen 
F i g . ß. I n f l u e n c e of o v a l i c i n o n D N A s y n t h e s i s i n l y m p h o c y t e s observed s h o r t l y a f t e r a d d i t i o n of 
m i t o g e n . 
Lymphocytes were stimulated as described in table XI . Incorporation of (3H)thymidine (0.5 Ci / 
mmol, 1 ^aCi/ml) during a one hour pulse was measured; concentration of ovalicin used: 2X 
10"7 mol/1. 
ced by 60-70% at this early phase of 
the cell cycle (table XIII). The inhibi-
tion of protein synthesis is increased to 
40% when the incubation period with 
the drug is extendedto40h (table XIII). 
This increased extent of inhibition may 
be the consequence of the blocked bio-
synthesis of D N A as has been discussed 
above. In this context we wish to men-
tion the Observation that the elongation 
process of protein biosynthesis as mea-
sured with ribosomes from stimulated 
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T a b l e X I I 
I n f l u e n c e of o v a l i c i n o n t h e i n c o r p o r a t i o n of ( i 4 C ) u r i d i n e i n t o R N A of s t i m u l a t e d l y m p h o c y t e s . 
1 a^g concanavalin A/ml and 3X10* 7 mol/1 ovalicin were added to 106 lymphocytes/ml (preincu-
bated for 12 h at 3 7 ° C). After 20 h 80 nCi ( 1 4C)uridine (specific radioactivity 414 Ci/mol) 
were added and the incubation continued for 1 h. 
additions incorporation of [ 1 4C] uridine during 
a one hour pulse (counts X min"1) 
+ Con A 2651 
+ ovalicin 
+ Con A 3419 
— ovalicin 
— Con A 1170 
+ ovalicin 
— Con A 1186 
— ovalicin 
T a b l e X I I I 
I n h i b i t i o n by o v a l i c i n of t h e i n c o r p o r a t i o n of ( * H ) l e u c i n e o r ( s H ) t h y m i d i n e i n t o a c i d i n s o l u b l e 
m a t e r i a l of s t i m u l a t e d l y m p h o c y t e s . 
Preincubated lymphocytes were stimulated essentially as described in table XI . Protein synthesis 
was followed by incorporation of (3H)Ieucine (specific radioactivity 57 Ci/mol when added 12 h 
after mitogen, 13 Ci/mol when added 36 h after mitogen) during a 2 h pulse essentially as described 
in table I. Incorporation of (3H)thymidine (specific radioactivity 0.5 Ci/mol) during a 2 h pulse 
was determined essentially as described in table III. Concentration of ovalicin: 2X10' 7 mol/1 
(added with Con A) . 
additions time of addition of 
radioactive precursor 
incorporation of 
[3H] leucine 
(counts X min*1) 
incorporation of 
[ 3H] thymidine 
(counts X min"1) 
+ ovalicin 12 5700 ± 139 443 ± 30 
— ovalicin 12 7741 ± 27 1094 ± 28 
+ ovalicin 36 4391 ± 62 13250 ± 934 
— ovalicin 36 8565 ± 308 40594 ± 1664 
lymphocytes in a cell-free system is not 
inhibited by 3 X 10*7 mol/1 ovalicin 
(table XIV). 
If the inhibition of protein biosyn-
thesis by the toxin is the direct conse-
quence of the inhibition of D N A syn-
thesis the formation of the histones 
should be affected particularly as has 
been shown above for cytosine arabino-
side by electrophoretic analysis (Fig. 2). 
However, this is not found. In the pre-
sence of ovalicin the formation of all 
proteins is uniformly reduced (data not 
shown). 
Summarizing the numerous observa-
tions reported we have to conclude that 
neither D N A nor protein synthesis is a 
direct target of ovalicin. This notion is 
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T a b l e X I V 
Effect of o v a l i c i n o n t h e p o l y r U d i r e c t e d s y n t h e s i s of p o l y p h e n y l a l a n i n e i n a c e l l - f r e e s y s t e m 
w i t h r i b o s o m e s f r o m s t i m u l a t e d l y m p h o c y t e s . 
Ribosomes were prepared from lymphocytes stimulated as described in table XI except that 
mercaptoethanol was added 23 h after addition of mitogen. The experiments with the cell-free 
system were performed as in table VIII except that the time of incubation was 15 min. 
additions incorporation of [3H] Phenylalanine 
(counts X min"1) 
no 2630 ± 494 
+ 0.7 X10' 6 mol/1 
ovalicin 2707 ± 310 
+ 1X10" 5 mol/1 
ovalicin 2545 ± 293 
without 
ribosomes 1040 ± 271 
supported by a comparison of the 
action of ovalicin with that of cyclo-
heximide or cytosine arabinoside on the 
transformation of small resting lym-
phocytes into large blast cells. After 
addition of the mitogen to a cell culture 
the average diameter of the cells increa-
ses up to the 48th hour of incubation as 
measured in the microscope. If cyclo-
heximide is added together with the 
mitogen the average diameter of the 
lymphocytes remains unchanged as in 
the absence of mitogen. Obviously con-
tinuous protein synthesis is required for 
blast cell formation. In the presence of 
cytosine arabinoside the average cell 
diameter increases up to the 24th hour 
almost as much as in the absence of this 
specific inhibitor of D N A synthesis. 
Düring the following day no further in-
crease is observed. The effect of ovali-
cin is very different from that of the 
drugs mentioned above. Here the for-
mation of blast cells continues up to 
two days of incubation although it is 
distinctly slower than in the absence of 
ovalicin (Fig. 6). In contrast D N A syn-
thesis, as measured simultaneously by 
incorporation of thymidine into the 
acid insoluble material of the cells, is 
inhibited very extensively (Fig. 6). 
These oberservations indicate that the 
mechanism of action of ovalicin is very 
different from that of specific inhibi-
tors of protein and D N A synthesis. 
Further investigations to pinpoint the 
target will be required. They promise to 
be rewarding since they will reveal the 
reason for the exceptionally high sensi-
tivity of lymphocytes to the toxin as 
well as a key reaction crucial for lym-
phocyte proliferation, since otherwise 
10"10 mol/1 ovalicin would not be ex-
pected to act inhibitory. 
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F i g . 6. I n h i b i t i o n of t h e t r a n s f o r m a t i o n of s m a l l l y m p h o c y t e s i n t o b l a s t c e l l s by o v a l i c i n , c y t o s t n e 
a r a b i n o s i d e o r c y c l o h e x i m i d e . 
Lymphocytes were stimulated as described in table X L Drugs were added togehter with the 
mitogen: 2X10" 7 M ovalicin, 1X10" 6 M cycloheximide or 1X10" 5 M cytosine arabinoside, respec-
tively. About 5X10 5 washed cells (in 0.25 ml) were mixed with 0.5 ml warm 0.5% agarose in 
phosphate-buffered saline, and applied to slides.The coated slides were treated with 0.5% glutaral-
dehyde in phosphate-buffered saline, washed three times for 5 min in destilled water, air-dried and 
Giemsastained [45]. The diameter of the stained cells was estimated at a magnification of 1:1250 in 
arbitrary units and the average diameter of 250 cells calculated. D N A synthesis (values in per 
cent are given in brackets) at 24, 36 and 48 h of incubation after addition of concanavalin A 
was determined by an one hour (3H)thymidine pulse (1 ^aCi/ml; 0.5 Ci/mmol) in 0.9 ml aliquots 
of the cell culture. 100% of D N A synthesis at 24, 36 and 48 h respectively: 19957 ± 8 4 , 50285 ± 
3286, 116805 + 222 counts X min' 1 , respectively. In the presence of cycloheximide or cytosine 
arabinoside the incorporation of thymidine into the acid-insoluble material of the cells is neglegible. 
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